Karman Holdings Inc.

# Signal Note: Driehaus Capital Initiates $99.2M Position in Karman Holdings Driehaus Capital's substantial entry into KRMN (1.36M shares) signals conviction in Karman's pipeline, likely centered on **KM-701** (GLP-1 receptor agonist) for obesity/diabetes, which has progressed through early-stage trials. The timing suggests positioning ahead of potential clinical readouts or FDA interactions, though specific near-term catalysts require clarification on current trial status. This represents a notable thesis shift for a growth-focused allocator with proven biotech selection track record.